Brokerage Amquity upgraded Alkem Laboratories to outperform from underperform and raised target price to 6,000 from 4,900

Wed 7 Oct 2026

New target price

6,000 rupees

Old target price

4,900 rupees

FY28 EPS growth estimate

2 percent

FY29 EPS growth estimate

6 percent

Resistance level

5350-5400

Heard on business television between 14:48:03 - 14:51:03 IST.

• Amquity upgraded Alkem to outperform from underperform, raising target to 6,000 rupees from 4,900.
• Brokerage said market is overly focused on diversification into MedTech and CDMO, expecting a gradual turnaround in these segments.
• Expected FY28 and FY29 EPS growth of 2% and 6% respectively.
• Technical analyst Kush said the stock is near a falling trendline resistance at 5350-5400 and suggested waiting a couple of days for confirmation of further upmove backed by volumes.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.